AdenoPaint Team
Meet The Team
Meet The Team
The Adenopaint team currently consists of an outstanding academic team and regulatory expert. The company has also contracted with well known wire manufactures, guidewire coating and sterilization and packaging companies.
Thomas White- CEO
Thomas White, PharmD, BCPS is a pharmacist who has spent the last decade working for several pharmaceutical companies as a director in medical affairs. His expertise includes key roles in earlier phases of drug development programs, initiation of clinical trials and roll-out of IND programs. He has also assisted in regulatory approval of drugs and led physician education initiatives to increase interest and awareness of new therapies approaching launch.
DR. MERVYN B. FORMAN-CMO
Dr. Forman is a practicing and translational research cardiologist who has pioneered the use of adenosine as a treatment for heart attacks. He has extensive experience in pre-clinical drug development and clinical trial designs. He was the principal investigator on a number of NIH sponsored grants and has published more than 200 research papers, abstracts and book chapters. He received his MD degree (‘74) and PhD (‘86) from the University Witwatersrand in South Africa and did his postdoctoral cardiology training in cardiology at Vanderbilt University where he was an Associate Professor of Medicine. He is a fellow of the American College of Cardiology and holds an academic appointment at Emory University.
DR. EDWIN K.JACKSON-CSO
Edwin K. Jackson, PhD- Adenosine and purines are a major focus of Dr. Jackson's research efforts. He is the holder of 17 issued patents with an additional 7 patents pending. All total, he has published more than 800 scientific publications including peer-reviewed primary research articles, abstracts, book chapters, and commentaries, many of which relate to adenosine or other purines. He is currently a full professor in the Department of Pharmacology and Molecular Biology at the University of Pittsburgh.
DR. ANTHONY M. LOWMAN-CTO
Anthony M. Lowman, Ph.D currently serves as the Provost and Senior Vice President of Academic Affairs at Rowan University. Additionally, he is the co-founder of Regeltec, Inc which is currently performing clinical trials for injectable hydrogels for the treatment of Degenerative Disk Disease. Dr. Lowman has published more than 100 refereed journal articles and book chapters and has more than 20 issued patents. Dr. Lowman is a fellow of the National Academy of Inventors and the American Institute of Medical and Biological Engineering. He received his degrees in chemical engineering at the University of Virginia (B.S., 1993) and at Purdue University (Ph.D., 1997) and has held academic appointments at Temple and Drexel.
DR. ERIK BREWER-
Head Product Development
Erik Brewer is a Scientist at Adenopaint with a background in drug delivery, formulation science, and medical device development. In addition, he is a full-time lecturer and Chair of Innovations and External Partnerships at Rowan University in Glassboro, New Jersey, as well as a Polymer Engineer at the Baltimore-based start-up, ReGelTec. Prior to joining Rowan, he was an Associate Scientist at Merck Research Lab’s Biopharmaceutics division. He is a graduate of Drexel University (BS ’07, PhD ’14), where he majored in Chemical Engineering
DR. BERNARD DE BRUYNE-
Clinical Consultant
Bernard De Bruyne, MD, PhD specializes in Cardiology, and Interventional Cardiology.
He is presently co-director of the Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium
Head, Invasive Cardiology, Cardiovascular Center Aalst, Aalst, Belgium and Professor of Cardiology at the University of Lausanne, Switzerland.He has co-authored 1145 scientific papers and presented works at national and international conferences. He is considered a pioneer in the development of the now widely used diagnostic standard of Free Fractional Reserve( FFR) to assess the severity of coronary artery stenosis.. FFR - guided PCI was utilized in the FAME trials to demonstrate improved outcomes compared with angio-guided PCI. More recently he has developed a thermodilution technique to assess blood flow and resistance in the coronary microcirculation. In 2018 he was recognized as among the 1% most cited scientists.
